Polen Capital Management Lowered Regeneron Pharmaceuticals (REGN) Position; 0 Analysts Are Bullish Eleven Biotherapeutics, Inc. (EBIO) Last Week

March 14, 2018 - By Vivian Park

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. The company was downgraded on Tuesday, January 19 by Citigroup. The rating was downgraded by Leerink Swann on Tuesday, January 19 to “Market Perform”. Citigroup maintained it with “Neutral” rating and $0.40 target in Wednesday, March 16 report. The rating was maintained by Leerink Swann on Saturday, August 15 with “Outperform”. See Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) latest ratings:

Polen Capital Management Llc decreased Regeneron Pharmaceuticals (REGN) stake by 13.41% reported in 2017Q3 SEC filing. Polen Capital Management Llc sold 212,706 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Polen Capital Management Llc holds 1.37 million shares with $614.17M value, down from 1.59 million last quarter. Regeneron Pharmaceuticals now has $36.74 billion valuation. The stock increased 1.09% or $3.67 during the last trading session, reaching $341.42. About 509,406 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since March 14, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 19 Hold. Therefore 39% are positive. Regeneron Pharmaceuticals Inc. had 120 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Thursday, January 18 by Piper Jaffray. BMO Capital Markets maintained it with “Hold” rating and $48400 target in Tuesday, July 18 report. The rating was downgraded by Robert W. Baird to “Underperform” on Tuesday, August 1. The rating was initiated by Gabelli with “Buy” on Tuesday, March 15. Bernstein initiated Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Wednesday, June 29 with “Outperform” rating. The company was upgraded on Friday, May 5 by Canaccord Genuity. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Neutral” rating by Chardan Capital Markets on Monday, August 31. The rating was upgraded by UBS to “Buy” on Monday, September 7. Credit Suisse upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Thursday, August 3 to “Buy” rating. Robert W. Baird downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Friday, August 5 to “Neutral” rating.

Since September 29, 2017, it had 0 insider purchases, and 3 selling transactions for $1.94 million activity. 1,000 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares with value of $325,600 were sold by GOLDSTEIN JOSEPH L. $900,000 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by BAKER CHARLES A. BROWN MICHAEL S sold $712,500 worth of stock.

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on May, 3. They expect $5.08 earnings per share, up 135.19% or $2.92 from last year’s $2.16 per share. REGN’s profit will be $546.58M for 16.80 P/E if the $5.08 EPS becomes a reality. After $4.46 actual earnings per share reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 13.90% EPS growth.

Investors sentiment is 1.17 in 2017 Q3. Its the same as in 2017Q2. It has no change, as 56 investors sold REGN shares while 165 reduced holdings. only 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Raymond James Fincl Serv Advsrs reported 0.01% stake. Tarbox Family Office holds 0% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 21 shares. Gabelli Funds Ltd Llc stated it has 0.02% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Nomura Hldgs, Japan-based fund reported 6,929 shares. King Luther Capital Mgmt Corporation holds 0% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 825 shares. Aviva Public Ltd Com invested in 0.12% or 49,846 shares. Sterling Mgmt Limited Liability Co reported 0.06% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). The United Kingdom-based Hsbc Holding Pcl has invested 0.03% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Shell Asset Management, a Netherlands-based fund reported 15,435 shares. Everence Management accumulated 0.18% or 1,737 shares. 16,225 were reported by Biondo Advsrs Ltd Llc. Envestnet Asset reported 23,411 shares. State Of Alaska Department Of Revenue accumulated 0.03% or 1,260 shares. Nordea Ab holds 0.03% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 28,470 shares. 55 were accumulated by Bartlett Company Ltd Llc.

Polen Capital Management Llc increased Celgene Corp (NASDAQ:CELG) stake by 148,333 shares to 5.23M valued at $762.83M in 2017Q3. It also upped Unilever Plc (NYSE:UL) stake by 34,236 shares and now owns 44,813 shares. Priceline Grp Inc (NASDAQ:PCLN) was raised too.

Investors sentiment increased to 2.25 in 2017 Q3. Its up 1.70, from 0.55 in 2017Q2. It improved, as 6 investors sold Eleven Biotherapeutics, Inc. shares while 5 reduced holdings. 4 funds opened positions while 2 raised stakes. 1.21 million shares or 1.55% less from 1.23 million shares in 2017Q2 were reported. Blackrock has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Barclays Public Limited Company owns 76 shares. Vanguard holds 0% or 184,304 shares in its portfolio. The Illinois-based Citadel Advisors Ltd Liability Co has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). The Massachusetts-based Panagora Asset Management Inc has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Northern reported 20,593 shares. Fiduciary Trust Company holds 20,000 shares or 0% of its portfolio. Price T Rowe Assocs Md has 52,700 shares. Bancorporation Of Ny Mellon has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Citigroup Incorporated holds 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) or 600 shares. 7,006 were accumulated by Morgan Stanley. 65,000 were accumulated by Bridgeway Management. Geode Capital Management owns 0% invested in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 56,222 shares. Royal Fincl Bank Of Canada reported 0% stake. The New York-based Virtu Fincl Llc has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO).

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics . The company has market cap of $36.77 million. It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. It currently has negative earnings. The companyÂ’s lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.